



## **As part of CLS expansion in Europe prostate cancer patients have been treated with CLS TRANBERG Thermal Therapy System for the first time in Italy**

**Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announced that two patients with localized prostate cancer have been safely treated with the TRANBERG® Thermal Therapy System at the San Luigi Gonzaga University Hospital in Turin, Italy. These are the first patient cases in Italy, and part of CLS commercialization and expansion in Europe.**

The urology department of the hospital, headed by Professor Francesco Porpiglia, has extensive experience in using US-fusion for targeted prostate biopsies and performs approximately 450 prostatectomies and more than 50 focal therapy cases a year. Since the workflow of the TRANBERG system for focal laser ablation is similar to that of targeted biopsies, it was a natural step forward for the clinic to implement the use of the TRANBERG system as a precise focal therapy treatment option.

“We are proud to be the first institute in Italy treating two patients with focal laser ablation using the TRANBERG system”, says Dr. De Luca who performed the treatments. “By using our own ultrasound-fusion system for image guidance, we were able to place the TRANBERG Laser Applicators exactly as planned. The integrated tissue temperature control feature of the TRANBERG system was essential to performing precise and safe ablations in these patients. Altogether, we are very pleased with the efficiency and ease of use of this system.”

“Italy is one of the key markets in Europe, both when it comes to market size and knowledge in focal therapy”, comments Perjan Pleunis, VP sales Europe at CLS. “The clinic directed by Professor Porpiglia in Turin is well renowned and has long experience in targeted prostate biopsies and focal therapy. The experiences from this clinic will facilitate our continued expansion both in Italy and on other key markets in Europe.”

### **About localized prostate cancer**

About 1.400.000 new cases per year of prostate cancer are reported worldwide with approximately 350.000 of them within EU. Although there are several prostate cancer treatment options, there is still an important unmet need for patients with localized prostate cancer who progress to the stage of intermediate risk. The currently available surgical options show significant risks and side effects related to urinary and erectile functions and quality of life.

### **About San Luigi Gonzaga University Hospital**

*The division of Urology at the department of Oncology, University of Turin, is composed by professionals from preclinical to translational research and clinic assistance for oncological diseases. It is sited in San Luigi Gonzaga University Hospital. The urology team, headed by Professor Francesco Porpiglia, manages all uro-oncological and all others genito-urinary*

*diseases. The most recent and modern technologies are available for diagnosis and treatment. Robotic and laparoscopic surgery have been developed in the last years, making San Luigi Hospital's Urology Division a pioneer Centre for many techniques, especially in the setting of translational surgery and focal therapy of cancer. Together with the clinical activity, also the teaching activity has a primary role, as this Department is the Centre for the Urology Residency Program. Their staff is continuously involved in and invited to attend the most prestigious international and national meetings. Their intensive scientific and research activity is widely recognized as demonstrated by the publications in the most famous international peer-reviewed journals.*

**For more information, please contact:**

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 705 90 11 40

E-mail: [dan.mogren@clinicallaser.com](mailto:dan.mogren@clinicallaser.com)

**About CLS**

*Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and a joint venture in Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB*

*For more information about CLS, please visit the Company's website: [www.clinicallaser.se](http://www.clinicallaser.se)*